The Commission brings together international experts in classical haematology to discuss the role of sexism in inequalities experienced by women, girls, and those assigned female at birth. 

Policy gaps were identified across heavy menstrual bleeding, time to bleeding disorder diagnoses, postpartum haemorrhage, hormone therapy-associated thrombosis, pregnancy-associated thrombosis, and maternal morbidity. 

As a member of the commission, TCRW Co-Director Dr Michelle Lavin's ongoing work on the impact of gynaecological bleeding in Women, Girls and Persons with the Potential to Menstruate (WGPPM), forms part of the evidence base for the ten actionable recommendations put forward the Commission. Recommendations include improved diagnosis and screening, including decreasing the time for diagnosis of bleeding disorders in females to 24 months by the end of 2035. 

Speaking at the event Minister Carroll MacNeill said:

"The work of The Lancet Haematology Commission is an important contribution to ensuring that women receive timely diagnoses, appropriate treatment and the high-quality care they deserve at every stage of life.”

You can learn more about the Commission here: Reducing mortality, improving outcomes, and establishing equity for women with classical haematological disease: a Lancet Haematology Commission

You can learn more about Dr Lavin's Research here: Dr Michelle Lavin